Genetics & Epigenetics Library
Every article, presentation, spotlight, and news item we've tagged to Genetics & Epigenetics.
Showing 1–24 of 176
APOE variants shape brain protein patterns before neurodegeneration
APOE ε2 and ε4 genetic variants produce distinct proteomic signatures that emerge before amyloid accumulation, mechanistically explaining their opposing effects on Alzheimer's disease risk. This proteomic mapping offers a foundation for identifying intervention points specific to genetic risk profiles rather than treating all cognitive decline uniformly.
Exceptional Longevity Modifying Allele APOE2 Promotes DNA Signaling Pathways Resisting Cellular Senescence in Human Neurons
APOE2, a genetic variant associated with exceptional longevity, activates DNA repair pathways and resists cellular senescence in neurons, while APOE4 exhibits elevated DNA damage and senescence markers. This mechanism extends beyond lipid metabolism, explaining APOE2's protective effects against neurodegeneration.
Alzheimer’s risk gene reveals hidden bone decline in women
APOE4, a major Alzheimer's disease risk gene, compromises bone quality in women through disruption of osteocytes—the long-lived cells responsible for maintaining bone microarchitecture—despite normal appearance on standard imaging. This finding suggests bone deterioration may serve as an early, detectable signal of neurodegenerative risk before cognitive symptoms emerge.
Additional Cover
APOE2, a rare genetic variant associated with exceptional longevity, activates cellular signaling pathways in neurons that resist senescence and maintain regenerative capacity. This finding identifies a molecular mechanism through which genetic variants can extend healthspan by preserving neuronal function and preventing age-related cellular decline.
Gene therapy penetrates brain barrier safely without liver toxicity
JCR Pharmaceuticals has advanced a modified AAV gene therapy platform that achieves efficient central nervous system delivery while minimizing off-target hepatic expression. In preclinical models of lysosomal storage disorders, the platform extended survival, preserved neurological and retinal function, and reduced markers of neuroinflammation and cellular accumulation.
APOE4 Increases Neurons’ Excitability Before Symptoms Appear
APOE4 carriers exhibit elevated neuronal excitability in specific hippocampal regions during youth, before cognitive symptoms manifest, with early excitability patterns predictive of later cognitive decline. This mechanism resembles accelerated aging and offers a window for intervention before irreversible neurodegeneration.
Gene therapy replaces repeated injections with single-dose adipocyte platform
Remedium Bio has secured $10 million in Series A funding to advance subcutaneous gene therapies designed to produce therapeutic proteins from fat tissue for multi-year duration with adjustable dosing. The platform targets replacement of repeated protein injections with single-administration gene therapy for cardiometabolic and chronic disease applications.
Roche gets CE mark for Alzheimer’s risk blood test
Roche has obtained CE mark approval for a blood test that identifies ApoE4 carriers, a genetic variant associated with increased Alzheimer's risk. This test streamlines risk stratification and treatment planning by enabling clinicians to prioritize patients for further evaluation and guide therapeutic decisions, particularly regarding amyloid-targeting therapies that carry differential risk profiles based on ApoE4 status.
Dog Gene Therapy Shows Early Safety in Aging Trial
Genflow Biosciences reports early safety and survival benefits in its SLAB gene therapy trial in 24 aging beagles, with no adverse events observed at three months. The study represents an emerging model in longevity research: using companion animals as a translational bridge between laboratory studies and human trials, where faster aging enables observation of long-term changes within years rather than decades.
Ultrasound Gene Delivery Solves Repeat Treatment Problem
SonoThera's ultrasound-based gene delivery platform addresses a fundamental constraint in genetic medicine: the inability to repeat treatments and the size limitations of viral vectors. The technology uses microbubbles and targeted ultrasound to open cellular pathways without immune recognition, potentially enabling the repeated interventions required for aging-related therapies.
APOE2 DNA Repair Mechanism Explains Neuronal Longevity
The APOE2 gene variant protects neurons through enhanced DNA repair mechanisms and resistance to cellular senescence, independent of its traditional role in lipid metabolism. This finding redirects therapeutic strategy toward genomic stability as a primary driver of neuronal longevity and dementia prevention.
Gene editing partnership reaches new in vivo success
Scribe Therapeutics and Eli Lilly have achieved a second milestone in developing in vivo CRISPR-based therapies for neurological and neuromuscular diseases. This advances the practical application of gene editing directly within the body, potentially enabling durable treatments delivered once or rarely, rather than requiring repeated interventions over a patient's lifetime.
Cellular silencing bypass extends gene therapy durability
Houdini Bio has developed a machine learning platform that redesigns therapeutic DNA to evade the HUSH complex, a cellular mechanism that silences foreign genetic material. This approach extends gene therapy durability while reducing required doses, with particular relevance for neurodegenerative diseases where sustained expression in long-lived neurons is critical to therapeutic outcome.
Gene therapy for aging advances to animal trials
Genflow Biosciences secured overwhelming shareholder approval for board leadership and capital authorization to advance its gene therapy pipeline targeting age-related diseases. The company is progressing GF-1002, its lead therapeutic candidate, through preclinical validation and early clinical evaluation in animal models with plans for human trials in metabolic disease.
Dual gene therapy targets muscle aging
Unlimited Bio has initiated a Phase 1/2a clinical trial combining AAV9-Follistatin and VEGF plasmid gene therapy to address age-related muscle loss and vascular insufficiency. The dual approach targets both muscle growth capacity and the circulatory support system that sustains muscle function—a systems-level intervention designed to address interconnected aspects of aging.
Adjustable Gene Therapy Turns Fat Cells Into Controllable Drug Factories
Remedium Bio has secured $10 million in Series A funding to develop adjustable gene therapies that reprogram fat cells to produce therapeutic proteins long-term. The platform's ability to modulate protein expression after treatment addresses a fundamental limitation of traditional gene therapy: the inability to change dosing once administered.
Meat Consumption May Benefit APOE4 Carriers
A 15-year Swedish cohort study found that unprocessed meat consumption was associated with preserved cognitive trajectory and reduced dementia risk in APOE ε4 carriers, effectively neutralizing the genotype's established cognitive penalty at higher intake levels. This finding challenges the assumption that ε4 carriers universally benefit from plant-forward diets and suggests ancestral dietary patterns may interact with genetic risk architecture in ways that modern nutritional guidelines do not account for.
Voyager pushes IV gene therapy for Alzheimer’s
Voyager Therapeutics has demonstrated that engineered gene therapies can reach the brain via intravenous infusion rather than invasive delivery, with preclinical data showing VY1706 achieved safe, predictable distribution to the central nervous system in non-human primates. This addresses a fundamental bottleneck in neurological drug development and positions tau-silencing approaches as candidates for clinical translation in Alzheimer's disease.
Single CRISPR Treatment Targets Inherited Heart Disease at Genetic Root
Scribe Therapeutics secured $25 million in funding to advance two CRISPR-based gene therapies targeting inherited cardiovascular disease—specifically lipoprotein(a) and triglyceride metabolism—toward human clinical trials. This represents a meaningful shift in cardiovascular medicine from lifelong management of risk factors toward one-time genetic intervention at the source of inherited disease.
Physical Fitness Is Negatively Associated With DNA Methylation‐Based Risk of Aging‐Related Diseases
Physical fitness metrics correlate with DNA methylation patterns of circulating proteins, revealing molecular pathways that link muscular strength, aerobic capacity, body composition, and cognitive function to reduced risk of age-related diseases. This molecular mapping enables patient-level disease risk stratification based on combined fitness and epigenetic measurements.
Telomere Restoration in Blood Cells Without Adverse Effects
Elixirgen is advancing two distinct therapeutic approaches for rare diseases: EXG-7001, a locally administered dystrophin mRNA for Duchenne muscular dystrophy, and EXG-34217, which uses engineered stem cells to achieve sustained telomere elongation in patients with telomere biology disorders. Early Phase 1/2 data demonstrates telomere lengthening without adverse events over 24 months, establishing proof of concept for a mutation-independent intervention in a class of diseases where cellular aging accelerates prematurely.
Neuronal APOE4-induced early hippocampal network hyperexcitability in Alzheimer’s disease pathogenesis
Young mice carrying the APOE4 gene variant show excessive electrical activity in the hippocampus before cognitive decline becomes apparent, a pattern driven by neuronal APOE4 expression itself. This early hyperexcitability represents a tractable target for intervention, as it can be reversed through modulation of the Nell2 pathway.
Scribe highlights CRISPR advances and STX-1150 data at ASGCT, EAS
Scribe Therapeutics is advancing engineered CRISPR platforms, including STX-1150, a liver-targeted epigenetic therapy that achieves sustained LDL-C reduction from a single dose without permanent genomic modification. The technology demonstrates enhanced specificity and potency in cardiometabolic applications, positioning epigenetic approaches as a precision intervention for cardiovascular risk factors.
Biotechs race to turn aging science into cell-based therapies
Multiple biotech companies are developing cell-based therapies targeting aging as an underlying condition rather than treating age-related diseases individually. The longevity biotech market is projected to grow from $9.86 billion in 2025 to $29.7 billion by 2034, driven by approaches using encapsulated cells, gene therapy, and stem cell platforms.